 phase II trial high-dos cisplatin dacarbazin lack efficaci high-dos cisplatin-bas therapi metastat melanoma cisplatin dacarbazin treatment metastat melanoma high-dos cisplatin dacarbazin patient metastat melanoma cisplatin day interv median age year rang year median karnofski perform statu rang measur evalu diseas site number patient lymph node lung soft tissu bone spleen adren gland site median cycl therapi rang cycl thirti patient evalu respons complet respons patient partial respons confid interv month site diseas lymph node lung soft tissu hematolog toxic grade equal neutropenia patient cycl thrombocytopenia patient cycl anemia patient nine neutropenia fever patient bacteremia nonhematolog toxic grade equal hypotens patient nausea vomit neuropathi ototox hypomagnesemia low object respons rate sever toxic regimen standard use patient metastat melanoma review cisplatin-bas therapi metastat melanoma dose-respons relationship use high-dos cisplatin treatment metastat melanoma